Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
| Revenue (TTM) | $3.12B |
| Gross Profit (TTM) | $1.24B |
| EBITDA | $689.44M |
| Operating Margin | 18.30% |
| Return on Equity | 61.30% |
| Return on Assets | 8.60% |
| Revenue/Share (TTM) | $9.87 |
| Book Value | $0.10 |
| Price-to-Book | 203.97 |
| Price-to-Sales (TTM) | 2.14 |
| EV/Revenue | 3.015 |
| EV/EBITDA | 15.09 |
| Quarterly Earnings Growth (YoY) | 157.10% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $348.30M |
| Float | $197.33M |
| % Insiders | 52.10% |
| % Institutions | 48.58% |
Volatility is currently contracting
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMRX and any ticker you trade — then tracks every position and per-strategy win rate.
